Resultados da busca - Stephen J. Schuster

Refinar Resultados
  1. 1
    Bispecific antibodies for the treatment of lymphomas: Promises and challenges

    Bispecific antibodies for the treatment of lymphomas: Promises and challenges por Stephen J. Schuster

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  2. 2
    Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy

    Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy por Elise A. Chong, Marco Ruella, Stephen J. Schuster

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Carta
    Salvar na lista
    Na minha lista:
  3. 3
    Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases

    Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases por Guillermo Garc�a-Manero, Stephen J. Schuster, Herbert Patrick, J. J. Martinez

    Publicado em 1999
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  4. 4
    BTK Inhibitors in Cancer Patients with COVID-19: “The Winner Will be the One Who Controls That Chaos” (Napoleon Bonaparte)

    BTK Inhibitors in Cancer Patients with COVID-19: “The Winner Will be the One Who Controls That Chaos” (Napoleon Bonaparte) por Elise A. Chong, Lindsey E. Roeker, Mazyar Shadman, Matthew S. Davids, Stephen J. Schuster, Anthony R. Mato

    Publicado em 2020
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  5. 5
    Outcomes of patients with relapsed/refractory diffuse large B‐cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era

    Outcomes of patients with relapsed/refractory diffuse large B‐cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era por Sarah Nagle, Kaitlin M. Woo, Stephen J. Schuster, Sunita D. Nasta, Edward A. Stadtmauer, Rosemarie Mick, Jakub Svoboda

    Publicado em 2013
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  6. 6
    Distribution of erythropoietin producing cells in rat kidneys during hypoxic hypoxia

    Distribution of erythropoietin producing cells in rat kidneys during hypoxic hypoxia por Kai‐Uwe Eckardt, Stephen T. Koury, Chorh Chuan Tan, Stephen J. Schuster, Brigitte Kaissling, Peter J. Ratcliffe, Armin Kurtz

    Publicado em 1993
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  7. 7
    Efficacy and safety of <scp>CD19</scp>‐directed <scp>CAR‐T</scp> cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the <scp>JULIET</scp>, <scp>ZUMA</scp>‐1, and <scp>TRANSCEND</scp> trials

    Efficacy and safety of <scp>CD19</scp>‐directed <scp>CAR‐T</scp> cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the <scp>JULIET<... por Jason R. Westin, Marie José Kersten, Gilles Salles, Jeremy S. Abramson, Stephen J. Schuster, Frederick L. Locke, Charalambos Andreadis

    Publicado em 2021
    Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  8. 8
    Comparable outcomes in chronic lymphocytic leukaemia (<scp>CLL</scp>) patients treated with reduced‐dose ibrutinib: results from a multi‐centre study

    Comparable outcomes in chronic lymphocytic leukaemia (<scp>CLL</scp>) patients treated with reduced‐dose ibrutinib: results from a multi‐centre study por Anthony R. Mato, Colleen Timlin, Chaitra S. Ujjani, Alan P Skarbnik, Christina Howlett, Rahul Banerjee, Chadi Nabhan, Stephen J. Schuster

    Publicado em 2017
    Obter o texto integral Obter o texto integral
    Carta
    Salvar na lista
    Na minha lista:
  9. 9
    Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial

    Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial por Stephen J. Schuster, Richard T. Maziarz, Elisha S. Rusch, Junlong Li, James Signorovitch, Vadim Romanov, Frederick L. Locke, David G. Maloney

    Publicado em 2020
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  10. 10
    Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial

    Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial por Richard T. Maziarz, Stephen J. Schuster, Vadim Romanov, Elisha S. Rusch, Junlong Li, James Signorovitch, David G. Maloney, Frederick L. Locke

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  11. 11
    Durable complete responses from therapy with combined epratuzumab and rituximab

    Durable complete responses from therapy with combined epratuzumab and rituximab por John P. Leonard, Stephen J. Schuster, Christos Emmanouilides, Félix Couture, Nick Teoh, William A. Wegener, Morton Coleman, David M. Goldenberg

    Publicado em 2008
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  12. 12
    Combined lenalidomide, low‐dose dexamethasone, and rituximab achieves durable responses in rituximab‐resistant indolent and mantle cell lymphomas

    Combined lenalidomide, low‐dose dexamethasone, and rituximab achieves durable responses in rituximab‐resistant indolent and mantle cell lymphomas por Tahamtan Ahmadi, Elise A. Chong, Amanda Gordon, Nicole A. Aqui, Sunita D. Nasta, Jakub Svoboda, Anthony R. Mato, Stephen J. Schuster

    Publicado em 2013
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  13. 13
    Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas

    Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas por Elise A. Chong, Tahamtan Ahmadi, Nicole A. Aqui, Jakub Svoboda, Sunita D. Nasta, Anthony R. Mato, Kristy M. Walsh, Stephen J. Schuster

    Publicado em 2015
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  14. 14
    PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR

    PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR por Elise A. Chong, J. Joseph Melenhorst, Simon F. Lacey, David E Ambrose, Vanessa Gonzalez, Bruce L. Levine, Carl H. June, Stephen J. Schuster

    Publicado em 2016
    Obter o texto integral Obter o texto integral
    Carta
    Salvar na lista
    Na minha lista:
  15. 15
    High Rate of Invasive Fungal Infections Following Nonmyeloablative Allogeneic Transplantation

    High Rate of Invasive Fungal Infections Following Nonmyeloablative Allogeneic Transplantation por Elisabeth A. Hagen, H Stern, David Porter, Kathleen M. Duffy, Karen Foley, Selina M. Luger, Stephen J. Schuster, Edward A. Stadtmauer, Mindy G. Schuster

    Publicado em 2003
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  16. 16
    Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy

    Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy por Elise A. Chong, Cécile Alanio, Jakub Svoboda, Sunita D. Nasta, Daniel J. Landsburg, Simon F. Lacey, Marco Ruella, Siddharth Bhattacharyya, E. John Wherry, Stephen J. Schuster

    Publicado em 2021
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  17. 17
    REDUCTION IN IMMUNOSUPPRESSION AS INITIAL THERAPY FOR POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER: ANALYSIS OF PROGNOSTIC VARIABLES AND LONG-TERM FOLLOW-UP OF 42 ADULT PATIENTS1

    REDUCTION IN IMMUNOSUPPRESSION AS INITIAL THERAPY FOR POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER: ANALYSIS OF PROGNOSTIC VARIABLES AND LONG-TERM FOLLOW-UP OF 42 ADULT PATIENTS1 por Donald E. Tsai, Christine Hardy, John E. Tomaszewski, Robert M. Kotloff, Kimberly M. Oltoff, Bradley G. Somer, Stephen J. Schuster, David Porter, Kathleen T. Montone, Edward A. Stadtmauer

    Publicado em 2001
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  18. 18
    Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)

    Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004) por Michael Wang, Stephen J. Schuster, Tycel Phillips, Izidore S. Lossos, André Goy, Simon Rule, Mehdi Hamadani, Nilanjan Ghosh, Craig B. Reeder, Evelyn Barnett, Marie-Laure Casadebaig Bravo, Peter Martin

    Publicado em 2017
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  19. 19
    Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma

    Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma por Rebecca L. Olin, Dan T. Vogl, David Porter, Selina M. Luger, Stephen J. Schuster, Donald E. Tsai, Don L. Siegel, Richard J. Cook, Patricia Mangan, K. Cunningham, Edward A. Stadtmauer

    Publicado em 2008
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  20. 20
    Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results

    Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results por Franck Morschhauser, John P. Leonard, Luis Fayad, Bertrand Coiffier, Marie-Odile Petillon, Morton Coleman, Stephen J. Schuster, Martin J.S. Dyer, Heather Horne, Nick Teoh, William A. Wegener, David M. Goldenberg

    Publicado em 2009
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:

Ferramentas de busca: